CY1120213T1 - Antαγωνιστες φθοριωμενης ιντεγκρινης - Google Patents
Antαγωνιστες φθοριωμενης ιντεγκρινηςInfo
- Publication number
- CY1120213T1 CY1120213T1 CY20171101252T CY171101252T CY1120213T1 CY 1120213 T1 CY1120213 T1 CY 1120213T1 CY 20171101252 T CY20171101252 T CY 20171101252T CY 171101252 T CY171101252 T CY 171101252T CY 1120213 T1 CY1120213 T1 CY 1120213T1
- Authority
- CY
- Cyprus
- Prior art keywords
- macular edema
- integrine
- antagonists
- compounds
- determined
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε φθοριωμένες ενώσεις του Χημικού Τύπου I και μεθόδους σύνθεσης αυτών των ενώσεων. Επίσης, η παρούσα εφεύρεση αφορά φαρμακευτικές συνθέσεις που περιέχουν τις φθοριωμένες ενώσεις της εφεύρεσης και μεθόδους θεραπείας της εκφύλισης της ωχράς κηλίδας, της διαβητικής αμφιβληστροειδοπάθειας (ΔΑ), του οιδήματος της ωχράς κηλίδας, του διαβητικού οιδήματος της ωχράς κηλίδας (ΔΟΩ) και του οιδήματος της ωχράς κηλίδας από απόφραξη φλέβας του αμφιβληστροειδούς (RVO), με χορήγηση αυτών των ενώσεων και των φαρμακευτικών συνθέσεων σε άτομα που την χρειάζονται.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361762087P | 2013-02-07 | 2013-02-07 | |
US201361900706P | 2013-11-06 | 2013-11-06 | |
PCT/US2014/015372 WO2014124302A1 (en) | 2013-02-07 | 2014-02-07 | Fluorinated integrin antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120213T1 true CY1120213T1 (el) | 2018-12-12 |
Family
ID=51300167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171101252T CY1120213T1 (el) | 2013-02-07 | 2017-11-29 | Antαγωνιστες φθοριωμενης ιντεγκρινης |
Country Status (24)
Country | Link |
---|---|
US (6) | US9518053B2 (el) |
EP (3) | EP3266782B1 (el) |
JP (2) | JP6494528B2 (el) |
KR (1) | KR102216091B1 (el) |
CN (2) | CN108690022B (el) |
AU (1) | AU2014214737B2 (el) |
BR (2) | BR112015019039B1 (el) |
CA (1) | CA2899321C (el) |
CY (1) | CY1120213T1 (el) |
DK (1) | DK2953948T3 (el) |
ES (2) | ES2763556T3 (el) |
HK (2) | HK1217696A1 (el) |
HR (1) | HRP20171873T1 (el) |
HU (1) | HUE035357T2 (el) |
IL (2) | IL240181A (el) |
LT (1) | LT2953948T (el) |
ME (1) | ME02938B (el) |
PL (1) | PL2953948T3 (el) |
PT (1) | PT2953948T (el) |
RS (1) | RS56711B1 (el) |
RU (1) | RU2698195C2 (el) |
SI (1) | SI2953948T1 (el) |
WO (1) | WO2014124302A1 (el) |
ZA (1) | ZA201505575B (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8901144B2 (en) * | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
ES2763556T3 (es) * | 2013-02-07 | 2020-05-29 | Scifluor Life Sciences Inc | Antagonistas fluorados de integrina |
JP6215335B2 (ja) | 2013-09-24 | 2017-10-18 | 富士フイルム株式会社 | 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体 |
WO2015175954A1 (en) * | 2014-05-16 | 2015-11-19 | Scifluor Life Sciences, Inc. | Alpha v integrin antagonist compositions |
EP3925959A1 (en) * | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
JP2018514568A (ja) | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
WO2017189828A1 (en) * | 2016-04-27 | 2017-11-02 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
WO2018009501A1 (en) * | 2016-07-05 | 2018-01-11 | The Rockefeller University | Tetrahydronaphthyridinepentanamide integrin antagonists |
MA46746A (fr) * | 2016-11-08 | 2019-09-18 | Bristol Myers Squibb Co | Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v |
DK3538528T3 (da) * | 2016-11-08 | 2021-02-15 | Bristol Myers Squibb Co | Pyrrolamider som alpha v-integrinhæmmere |
US10253025B2 (en) | 2017-03-30 | 2019-04-09 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
WO2021231581A1 (en) | 2020-05-12 | 2021-11-18 | Scifluor Life Sciences, Inc. | METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED α V INTEGRIN ANTAGONISTS |
WO2023230042A1 (en) * | 2022-05-23 | 2023-11-30 | Ocuterra Therapeutics, Inc. | Treating diabetic retinopathy using an integrin inhibitor |
WO2024006248A1 (en) * | 2022-06-27 | 2024-01-04 | Ocuterra Therapeutics, Inc. | Stable ophthalmic formulations of a fluorinated integrin antagonist |
CN116239665A (zh) * | 2023-03-10 | 2023-06-09 | 山东大学 | Ncf4在制备调控炎症小体激活的制剂中的应用和作为炎症性疾病的治疗靶点中的应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1318254C (en) | 1988-01-06 | 1993-05-25 | Munehiro Tomikawa | Inhibitory agent of hepatic fibrosis containing pantethine |
DE69220050T2 (de) | 1991-04-01 | 1998-01-22 | Univ Duke | Verfahren zur inhibierung der fibrose |
US5501969A (en) | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
JP3818322B2 (ja) | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
US6544767B1 (en) | 1994-10-27 | 2003-04-08 | Axys Pharmaceuticals, Inc. | Cathespin O2 protease |
US5736357A (en) | 1994-10-27 | 1998-04-07 | Arris Pharmaceutical | Cathespin O protease |
US5645839A (en) | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
US6211184B1 (en) | 1996-08-29 | 2001-04-03 | Merck & Co., Inc. | Integrin antagonists |
WO1998008528A1 (en) | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
WO1999030709A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
DE69829996T2 (de) | 1997-12-17 | 2006-02-23 | Merck & Co., Inc. (A New Jersey Corp.) | Integrin-rezeptor-antagonisten |
US6066648A (en) * | 1997-12-17 | 2000-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
CN1284955A (zh) * | 1997-12-17 | 2001-02-21 | 麦克公司 | 整联蛋白受体拮抗剂 |
ES2243016T3 (es) * | 1997-12-17 | 2005-11-16 | MERCK & CO., INC. | Antagonistas de receptores de integrinas. |
US6117445A (en) | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
US6677360B2 (en) * | 1998-12-16 | 2004-01-13 | Bayer Aktiengesellschaft | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
NZ512339A (en) * | 1998-12-16 | 2003-03-28 | Bayer Ag | New biphenyl and biphenyl-analogous compounds as integrin antagonists |
US6291503B1 (en) * | 1999-01-15 | 2001-09-18 | Bayer Aktiengesellschaft | β-phenylalanine derivatives as integrin antagonists |
SK17442001A3 (sk) * | 1999-06-02 | 2002-03-05 | Merck & Co., Inc. | Deriváty kyseliny nonánovej, farmaceutický prostriedok s ich obsahom a ich použitie |
US6407241B1 (en) | 1999-11-08 | 2002-06-18 | Merck & Co., Inc. | Process and intermediates for the preparation of imidazolidinone αv integrin antagonists |
US6455539B2 (en) * | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
WO2001053297A1 (en) | 2000-01-20 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
AU780988B2 (en) | 2000-01-24 | 2005-04-28 | Merck & Co., Inc. | Alpha V integrin receptor antagonists |
WO2001062292A1 (fr) | 2000-02-22 | 2001-08-30 | Suntory Limited | Medicaments preventifs ou therapeutiques pour traiter la fibrose et contenant des inhibiteurs de chymase comme ingredients actifs |
GB0011817D0 (en) * | 2000-05-16 | 2000-07-05 | Pharmacia & Upjohn Spa | Antagonists of integrin receptors |
ATE353219T1 (de) * | 2000-07-26 | 2007-02-15 | Merck & Co Inc | Alpha v integrin-rezeptor-antagonisten |
WO2002022616A2 (en) | 2000-09-14 | 2002-03-21 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
CA2421652A1 (en) | 2000-09-14 | 2002-03-21 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
EP1322311A1 (en) | 2000-09-18 | 2003-07-02 | Merck & Co., Inc. | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
EP1444231A4 (en) | 2001-11-06 | 2005-11-09 | Merck & Co Inc | AMINO SALTS OF AN INTEGRIN RECEPTOR ANTAGONIST |
US20040053968A1 (en) * | 2001-12-28 | 2004-03-18 | Hartman George D. | Methods and compositions for treating peridontal disease |
CA2499149A1 (en) * | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Mannitol formulation for integrin receptor antagonist |
US20050043344A1 (en) | 2002-12-20 | 2005-02-24 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists derivatives |
ATE399542T1 (de) | 2003-10-01 | 2008-07-15 | Merck Patent Gmbh | Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel |
WO2011060395A1 (en) | 2009-11-16 | 2011-05-19 | Schering Corporation | Cyclic ureas useful as hiv inhibitors |
WO2011150156A2 (en) | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
EP2707036A4 (en) | 2011-05-09 | 2015-03-18 | Allegro Pharmaceuticals Inc | INTEGRIN RECEPTOR ANTAGONISTS AND METHOD FOR THEIR USE |
JP2014518232A (ja) | 2011-06-28 | 2014-07-28 | バイエル・ヘルスケア・エルエルシー | ソラフェニブを含有する眼科用局所医薬組成物 |
US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
ES2763556T3 (es) | 2013-02-07 | 2020-05-29 | Scifluor Life Sciences Inc | Antagonistas fluorados de integrina |
EP3925959A1 (en) | 2015-02-19 | 2021-12-22 | OcuTerra Therapeutics, Inc. | Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof |
JP2018514568A (ja) | 2015-04-30 | 2018-06-07 | サイフルーア ライフ サイエンシズ インコーポレイテッド | テトラヒドロナフチリジニルプロピオン酸誘導体およびその使用法 |
US10253025B2 (en) | 2017-03-30 | 2019-04-09 | Scifluor Life Sciences, Inc. | Method of making tetrahydronaphthyridinyl nonanoic acid compounds |
-
2014
- 2014-02-07 ES ES17186012T patent/ES2763556T3/es active Active
- 2014-02-07 KR KR1020157022414A patent/KR102216091B1/ko active IP Right Grant
- 2014-02-07 WO PCT/US2014/015372 patent/WO2014124302A1/en active Application Filing
- 2014-02-07 BR BR112015019039-1A patent/BR112015019039B1/pt active IP Right Grant
- 2014-02-07 LT LTEP14749249.0T patent/LT2953948T/lt unknown
- 2014-02-07 AU AU2014214737A patent/AU2014214737B2/en active Active
- 2014-02-07 CN CN201810749035.3A patent/CN108690022B/zh active Active
- 2014-02-07 EP EP17186012.5A patent/EP3266782B1/en active Active
- 2014-02-07 ME MEP-2017-281A patent/ME02938B/me unknown
- 2014-02-07 RS RS20171250A patent/RS56711B1/sr unknown
- 2014-02-07 US US14/766,322 patent/US9518053B2/en active Active
- 2014-02-07 CN CN201480020172.3A patent/CN105246889B/zh active Active
- 2014-02-07 BR BR122019026750-2A patent/BR122019026750B1/pt active IP Right Grant
- 2014-02-07 EP EP14749249.0A patent/EP2953948B1/en active Active
- 2014-02-07 CA CA2899321A patent/CA2899321C/en active Active
- 2014-02-07 EP EP19205757.8A patent/EP3674301A1/en not_active Withdrawn
- 2014-02-07 JP JP2015557136A patent/JP6494528B2/ja active Active
- 2014-02-07 RU RU2015137785A patent/RU2698195C2/ru active
- 2014-02-07 PT PT147492490T patent/PT2953948T/pt unknown
- 2014-02-07 HU HUE14749249A patent/HUE035357T2/en unknown
- 2014-02-07 ES ES14749249.0T patent/ES2651162T3/es active Active
- 2014-02-07 SI SI201430481T patent/SI2953948T1/en unknown
- 2014-02-07 DK DK14749249.0T patent/DK2953948T3/en active
- 2014-02-07 PL PL14749249T patent/PL2953948T3/pl unknown
-
2015
- 2015-07-28 IL IL240181A patent/IL240181A/en active IP Right Grant
- 2015-08-03 ZA ZA2015/05575A patent/ZA201505575B/en unknown
-
2016
- 2016-05-04 IL IL245471A patent/IL245471B/en active IP Right Grant
- 2016-05-16 HK HK16105603.0A patent/HK1217696A1/zh unknown
- 2016-11-04 US US15/343,823 patent/US9717729B2/en active Active
-
2017
- 2017-06-27 US US15/633,946 patent/US10106537B2/en active Active
- 2017-11-29 CY CY20171101252T patent/CY1120213T1/el unknown
- 2017-12-04 HR HRP20171873TT patent/HRP20171873T1/hr unknown
-
2018
- 2018-06-22 HK HK18108084.0A patent/HK1248677A1/zh unknown
-
2019
- 2019-03-05 JP JP2019039410A patent/JP2019108377A/ja active Pending
- 2019-05-13 US US16/409,960 patent/US20190263810A1/en not_active Abandoned
-
2020
- 2020-08-12 US US16/991,138 patent/US11685737B2/en active Active
-
2023
- 2023-06-21 US US18/212,324 patent/US20240140942A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120213T1 (el) | Antαγωνιστες φθοριωμενης ιντεγκρινης | |
CY1124061T1 (el) | Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες | |
CY1125436T1 (el) | Αναστολεις dna-pk | |
CY1120832T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
CY1121153T1 (el) | Παραγωγα εξενδινης-4 ως διπλοι glp1/gιp- ή τριγωνικοι αγωνιστες glp1/gιp/γλυκαγονης | |
EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
CY1123996T1 (el) | Υποκατεστημενα παραγωγα οξοπυριδινης | |
CY1119110T1 (el) | Ρυθμιστες ρ2χ7 | |
CY1122329T1 (el) | Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
CY1123953T1 (el) | Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης | |
CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
EA201890159A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
CY1119047T1 (el) | Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4 | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
BR112017017888A2 (pt) | derivados fluorados do ácido tetraidronaftiridinil nonanoico derivados e usos destes | |
EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
EA201600478A1 (ru) | Новые индазолкарбоксамиды, способы их получения, содержащие их фармацевтические препараты и их применение для изготовления лекарственных средств | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
CY1119615T1 (el) | Διπλα εκλεκτικοι αναστολεις ρι3 δελτα και γαμμα κινασης | |
CY1122441T1 (el) | Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους | |
EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич |